Fumarylacetoacetate hydrolase domain-containing protein 2B (EC 3.-.-.-)
1_MLVSG 6_ RRRLL 11_ TALLQ 16_ AQKWP 21_ FQPSR 26_ DMRLV 31_ QFRAP 36_ HLVGP 41_ HLGLE 46_ TGNGG 51_ GVINL 56_ NAFDP 61_ TLPKT 66_ MTQFL 71_ EQGEA 76_ TLSVA 81_ RRALA 86_ AQLPV 91_ LPWSE 96_ VTFLA 101_ PVTWP 106_ DKVVC 111_ VGMNY 116_ VDHCK 121_ EQNVP 126_ VPKEP 131_ IIFSK 136_ FASSI 141_ VGPYD 146_ EVVLP 151_ PQSQE 156_ VDWEV 161_ ELAVV 166_ IGKKG 171_ KHIKA 176_ TDAMA 181_ HVAGF 186_ TVAHD 191_ VSARD 196_ WLTRR 201_ NGKQW 206_ LLGKT 211_ FDTFC 216_ PLGPA 221_ LVTKD 226_ SVADP 231_ HNLKI 236_ CCRVN 241_ GEVVQ 246_ SSNTN 251_ QMVFK 256_ TEDLI 261_ AWVSQ 266_ FVTFY 271_ PGDVI 276_ LTGTP 281_ PGVGV 286_ FRKPP 291_ VFLKK 296_ GDEVQ 301_ CEIEE 306_LGVII
1: Tautomerase that converts enol-oxaloacetate, a strong inhibitor of succinate dehydrogenase, to the physiological keto form of oxaloacetate (PubMed:38287013). It is thereby required to maximize aerobic respiration efficiency by preventing succinate dehydrogenase inhibition (PubMed:38287013)